XML 75 R63.htm IDEA: XBRL DOCUMENT v3.25.1
Note 14 - Strategic Alliances (Details Textual) - USD ($)
$ / shares in Units, $ in Thousands
1 Months Ended 3 Months Ended 25 Months Ended 39 Months Ended
Mar. 16, 2025
Mar. 08, 2023
Sep. 14, 2021
Jun. 18, 2021
May 05, 2020
Sep. 30, 2024
Mar. 31, 2025
Mar. 31, 2024
Mar. 31, 2023
Mar. 31, 2025
Mar. 31, 2025
Jan. 07, 2025
Dec. 31, 2024
Sep. 29, 2024
Oct. 01, 2019
Payments to Acquire Investments             $ 8,000 $ (0)              
Revenue from Contract with Customer, Excluding Assessed Tax             149,952 173,686              
Corporate Joint Venture [Member] | LeaderMed Joint Venture [Member]                              
Revenue from Contract with Customer, Excluding Assessed Tax     $ 1,000                        
Subsidiary, Ownership Percentage, Parent     47.00%                        
LeaderMed [Member] | Corporate Joint Venture [Member] | LeaderMed Joint Venture [Member]                              
Payments to Acquire Interest in Joint Venture     $ 11,000                        
Subsidiary, Ownership Percentage, Noncontrolling Owner     53.00%                        
Collaboration and License Agreement With Entera [Member] | Entera Ordinary Shares [Member]                              
Investment Owned, Shares Purchased (in shares) 3,685,226                            
Shares Purchased, Price Per Share (in dollars per share) $ 2.17                            
Payments to Acquire Investments $ 8,000                            
Collaboration and License Agreement With Entera [Member] | Opko [Member]                              
Ownership, Percentage 60.00%                            
Collaboration and License Agreement With Entera [Member] | Opko [Member] | Entera Discontinuing Funding [Member]                              
Ownership, Percentage 85.00%                            
Collaboration and License Agreement With Entera [Member] | Entera [Member]                              
Ownership, Percentage 40.00%                            
Collaboration and License Agreement With Entera [Member] | Entera [Member] | Entera Discontinuing Funding [Member]                              
Ownership, Percentage 15.00%                            
BARDA Agreement [Member]                              
Collaborative Arrangement, Supplement for Advance of Development           $ 26,900                  
Revenue from Contract with Customer, Excluding Assessed Tax           24,100 7,000 $ 2,200              
Collaborative Arrangement, Value           110,000               $ 59,000  
Collaborative Arrangement, Value, Including Milestones           $ 205,000               $ 168,600  
Aggregate Transaction Price Allocated to Remaining Performance Obligations, Excluding Unexercised Contract Options, Amount             78,000                
Merck Agreement [Member] | Merck Sharp & Dohme LLC [Member]                              
Revenue from Contract with Customer, Excluding Assessed Tax   $ 50,000                          
Collaborative Arrangement, Development Milestone Payment   $ 860,000                   $ 12,500      
Collaborative Arrangement, Development Costs                   $ 26,100          
Development and License Agreement [Member] | NICOYA Macau Limited [Member] | EirGen [Member]                              
Revenue from Contract with Customer, Excluding Assessed Tax       $ 5,000         $ 2,500            
Collaborative Arrangement, Development Milestone Payment       115,000                      
Collaborative Agreement, Delayed Payment       $ 5,000                      
Collaborative Agreement, Delayed Payment Received, Cumulative                 $ 2,500            
Collaborative Arrangement, Period Following First Commercial Sale (Year)       10 years                      
Development and License Agreement [Member] | Vifor Fresenius Medical Care Renal Pharma Ltd. [Member] | EirGen [Member]                              
Collaborative Arrangement, Maximum Regulatory Milestone Payments         $ 15,000                    
Collaborative Arrangement, Sales Milestone Payment         200,000                    
Collaborative Agreement, Option, Sales Milestone Payments         555,000                    
Development and License Agreement [Member] | Vifor Fresenius Medical Care Renal Pharma Ltd. [Member] | EirGen [Member] | First Marketing Approval of Rayaldee in Europe [Member]                              
Revenue from Contract with Customer, Excluding Assessed Tax         3,000                    
Development and License Agreement [Member] | Vifor Fresenius Medical Care Renal Pharma Ltd. [Member] | EirGen [Member] | Germany Price Approval by Local Sick Fund Association [Member]                              
Revenue from Contract with Customer, Excluding Assessed Tax         $ 7,000                    
Pfizer Agreement [Member] | Pfizer Inc. [Member]                              
Revenue from Contract with Customer, Excluding Assessed Tax                     $ 175,000        
Collaborative Arrangement, Maximum Regulatory Milestone Payments                             $ 275,000
Revenue, Remaining Performance Obligation, Amount                             295,000
Contract with Customer, Liability             $ 0     $ 0 $ 0   $ 0    
Pfizer Agreement [Member] | Pfizer Inc. [Member] | Minimum [Member]                              
Collaborative Agreements, Each Milestone Payment                             20,000
Pfizer Agreement [Member] | Pfizer Inc. [Member] | Maximum [Member]                              
Collaborative Agreements, Each Milestone Payment                             $ 90,000